ArticleJournal of hematopathology2025
A novel IKZF1::FAM3C fusion associated with inversion of chromosome 7, inv(7)(p13q32), in relapsed acute myeloid leukemia.
Article in Journal of hematopathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAcute myeloid leukemia (AML) is characterized by myeloid blasts in the bone marrow and peripheral blood, and it is a highly heterogenous disease genetically. Although our understanding of AML genetics has advanced considerably, disease relapse continues to pose a significant therapeutic hurdle. CASE PRESENTATION: Here, we report a case of relapsed AML following allogeneic stem cell transplantation (alloSCT) with a novel in-frame IKZF1::FAM3C fusion detected by RNA sequencing. Karyotype analysis revealed a pericentric inversion of chromosome 7, inv(7)(p13q32), which is the likely mechanism for this fusion. While IKZF1 deletions are a common feature in B-cell acute lymphoblastic leukemia (B-ALL) and are linked to poor outcomes, especially in children, they are rarely reported in AML. To our knowledge, gene fusions involving IKZF1 have not been previously described in AML, although deletion of the short arm of chromosome 7 involving the IKZF1 gene is relatively common.
conclusionsThis case broadens the spectrum of IKZF1 rearrangements in hematologic malignancies and suggests a potential role for disrupted Ikaros function in AML pathogenesis.
Indexed as
Identifiers
41269428What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.